NASDAQ · PTE
Healthcare · Biotechnology
$0.24
Down-$0.00 (-0.82%)
Updated Sep 11, 2026, 1:01 AM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
PTE does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning PTE.
PTE research
Company profile and research snapshot.
PolarityTE, Inc., a clinical stage biotechnology company, develops and commercializes a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences in the United States. The company operates in two segments, Regenerative Medicine Products and Contract Services. It offers SkinTE, a tissue product used to repair, reconstruction, replacement, and supplementation of skin in patients for the treatment of acute or chronic wounds, burns, surgical reconstruction events, scar revision, or removal of dysfunctional skin grafts, as well as contract research services. The company also develops SkinTE Cryo allows multiple deployments from one original harvest through a cryopreservation process; SkinTE point-of-care device to permit the processing and deployment of SkinTE immediately following the initial harvest at the point-of-car; PTE 11000, an allogenic, biologically active dressing for use in wound care and aesthetics to accelerate healing of skin; and other tissue regeneration products. PolarityTE, Inc. is headquartered in Salt Lake City, Utah.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Dec 28, 2022 | Northland Capital Markets | Outperform | — |
| May 12, 2020 | Cantor Fitzgerald | Overweight | — |
| May 4, 2020 | HC Wainwright & Co. | Neutral | — |
| Nov 13, 2019 | Piper Jaffray | Overweight | — |
| Nov 11, 2019 | Cantor Fitzgerald | Overweight | — |
No generated briefing is available yet.
Zacks Investment Research · Apr 25, 2023
PolarityTE, Inc. (PTE) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Benzinga · Dec 28, 2022
Northland Capital Markets has decided to maintain its Outperform rating of PolarityTE (NASDAQ:PTE) and lower its price target from $1.25 to $1.00. Shares of PolarityTE are trading down 4.11% over the last 24 hours, at $0.70 per share. A move to $1.00 would account for a 42.86% increase from the current share price. About PolarityTE PolarityTE Inc is a commercial-stage biotechnology and regenerative biomaterials company. It's focused on transforming the lives of patients by discovering, designing and developing regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences. Its product includes SkinTE used for repair, reconstruction, replacement or regeneration of ...Full story available on Benzinga.com
Zacks Investment Research · Oct 13, 2022
PolarityTE, Inc. (PTE) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks Investment Research · May 16, 2022
PolarityTE, Inc. (PTE) delivered earnings and revenue surprises of -25% and 12.82%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning PTE.
No results
No recent SID articles mention PTE.
